Abstract
Glutamate is the most ubiquitous of the fast excitatory neurotransmitters in the central nervous system. In the process, glutamate fulfills numerous physiological functions, but also plays an important role in the pathophysiology of a variety of psychiatric and behavioral disorders such as schizophrenia. Recently, modulation of glutamatergic neurotransmission has been suggested to be involved in the mechanisms of action of antipsychotic drugs. Thus, pharmacological manipulation of glutamatergic transmission may be a feasible therapeutic strategy for treatment of schizophrenia. In this review article, we focus on the role of central glutamatergic neurotransmission in the pathogenesis and pharmacotherapy of schizophrenia and the development of new drugs targeting glutamate brain systems.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
